Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 31, 2021

BD receives FDA EUA for combination antigen test

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Becton, Dickinson and Company’s (BD) new rapid antigen test that can identify SARS-CoV-2, influenza A and influenza B in a single test.

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Becton, Dickinson and Company’s (BD) new rapid antigen test that can identify SARS-CoV-2, influenza A and influenza B in a single test.

The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B assay runs on the BD Veritor Plus System and uses the same simple workflow as other rapid tests run on the system to provide a result in 15 minutes.

The test differentiates between SARS-CoV-2, influenza A and influenza B and delivers individual, definitive positive or negative digital display readouts for all three.

Intended for people suspected of having Covid-19, influenza A or influenza B by a health care provider, the test can be carried out within six days of developing symptoms.

BD life sciences president Dave Hickey said: “Given that symptoms for Covid-19 and the flu are very similar, having the ability to run a rapid combination test to distinguish between these viral infections may help save time and resources.

“BD will continue to offer both individual tests for SARS-CoV-2 and influenza A+B, as well as the new combination tests, to give health care providers the option to run the test that is most appropriate for their patients.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The company intends to introduce the combination test in June for the 2021-2022 flu season.

The US has more than 70,000 active BD Veritor Systems in use at hospitals, clinician offices, urgent care centres, nursing homes, retail pharmacies, schools, businesses and other testing sites.

BD noted that the system, which is slightly bigger than a cell phone, has one-button functionality, workflow flexibility and an uncomplicated design, is a perfect solution for settings without laboratory staff.

In February, BD received the CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU